Robin Dretler, MD
Infectious Disease · Decatur, GANPI 1871545459
Payments from drug & device makers
Across 518 payments — averaging $3486.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- Viiv Healthcare Company$276K
- Janssen Research & Development, LLC$34K
- Gilead$3K
- AbbVie$671
- Cumberland Pharmaceuticals, Inc.$322
- plus $2K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 183 | $1,489,305 |
| Viiv Healthcare Company | 147 | $275,652 |
| Janssen Research & Development, LLC | 5 | $34,298 |
| Gilead | 54 | $3,199 |
| AbbVie(2 entities) | 27 | $671 |
| Cumberland Pharmaceuticals, Inc. | 4 | $322 |
| Janssen Scientific Affairs, LLC | 3 | $276 |
| Insmed, Inc. | 8 | $265 |
| Johnson & Johnson | 19 | $264 |
| Astellas Pharma US Inc | 6 | $193 |
| Smith+Nephew | 10 | $186 |
| La Jolla Pharmaceutical Company | 8 | $177 |
| Janssen Products, LP | 2 | $171 |
| Melinta Therapeutics, LLC | 6 | $114 |
| Organogenesis Inc. | 4 | $98 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $97 |
| Kerecis Limited | 1 | $54 |
| Theratechnologies Inc. | 3 | $53 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Amgen | 2 | $35 |
| Integra Lifesciences Corporation | 1 | $32 |
| Aroa Biosurgery Incorporated | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Mylan Institutional Inc. | 1 | $22 |
| Next Science LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| GSK | 1 | $14 |
| Hydrofera LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Reapplix Inc. | 1 | $13 |
| Reprise Biomedical, Inc. | 1 | $8 |
How this compares
$1,805,836 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Decatur
- Anson WurapaDecatur$742K
- Alexandra DretlerDecatur$203K
- Vincent MarconiDecatur$20K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.